Enterohepatic circulation of bile acids and their emerging roles on glucolipid metabolism

被引:37
作者
Chen, Meng-jun [1 ]
Liu, Chen [1 ]
Wan, Yue [1 ]
Yang, Lei [1 ]
Jiang, Shu [1 ]
Qian, Da-wei [1 ]
Duan, Jin-ao [1 ]
机构
[1] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, 138 Xianlin Rd, Nanjing 210023, Peoples R China
基金
中国国家自然科学基金;
关键词
Enterohepatic circulation; Bile acids; FXR; TGR5; FARNESOID-X-RECEPTOR; GLUCAGON-LIKE PEPTIDE-1; FIBROBLAST GROWTH FACTOR-19; LOW-DENSITY LIPOPROTEIN; NUCLEAR RECEPTORS; LIPID-METABOLISM; GENE-EXPRESSION; LIVER STEATOSIS; INSULIN SENSITIVITY; TRIGLYCERIDE LEVELS;
D O I
10.1016/j.steroids.2020.108757
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bile acids (BAs) are amphiphilic molecules with a nonpolar steroid carbon skeleton and a polar carboxylate side chain. Recently, BAs have aroused the attention of scholars due to their potential roles on metabolic diseases. As important endogenous ligands, BAs are wildly active in the entemhepatic circulation, during which microbiota play a significant role in promoting the hydrolysis and dehydroxylation of BAs. Besides, many pathways initiated by BAs including glucolipid metabolism and inflammation signaling pathways have been reported to regulate the host metabolism and maintain immune homeostasis. Herein, the characteristics on the entemhepatic circulation and metabolism of BAs are systematically summarized. Moreover, the regulation mechanism of the glucolipid metabolism by BAs is intensively discussed. Worthily, FXR and TGR5, which are involved in glucolipid metabolism, are the prime candidates for targeted therapies of chronic metabolic diseases such as diabetes and hypercholestemlemia.
引用
收藏
页数:10
相关论文
共 158 条
[1]   Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease [J].
Abenavoli, Ludovico ;
Falalyeyeva, Tetyana ;
Boccuto, Luigi ;
Tsyryuk, Olena ;
Kobyliak, Nazarii .
PHARMACEUTICALS, 2018, 11 (04)
[2]   Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers [J].
Adrian, T. E. ;
Gariballa, S. ;
Parekh, K. A. ;
Thomas, S. A. ;
Saadi, H. ;
Al Kaabi, J. ;
Nagelkerke, N. ;
Gedulin, B. ;
Young, A. A. .
DIABETOLOGIA, 2012, 55 (09) :2343-2347
[3]   DEOXYCHOLATE IS AN IMPORTANT RELEASER OF PEPTIDE-YY AND ENTEROGLUCAGON FROM THE HUMAN COLON [J].
ADRIAN, TE ;
BALLANTYNE, GH ;
LONGO, WE ;
BILCHIK, AJ ;
GRAHAM, S ;
BASSON, MD ;
TIERNEY, RP ;
MODLIN, IM .
GUT, 1993, 34 (09) :1219-1224
[4]   Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration [J].
Alvarez-Sola, Gloria ;
Uriarte, Iker ;
Ujue Latasa, M. ;
Fernandez-Barrena, Maite G. ;
Urtasun, Raquel ;
Elizalde, Maria ;
Barcena-Varela, Marina ;
Jimenez, Maddalen ;
Chang, Haisul C. ;
Barbero, Roberto ;
Catalan, Victoria ;
Rodriguez, Amaia ;
Fruhbeck, Gema ;
Gallego-Escuredo, Jose M. ;
Gavalda-Navarr, Aleix ;
Villarroya, Francesc ;
Rodriguez-Ortigosa, Carlos M. ;
Corrales, Fernando J. ;
Prieto, Jesus ;
Berraondo, Pedro ;
Berasain, Carmen ;
Avila, Matias A. .
GUT, 2017, 66 (10) :1818-1828
[5]   Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor [J].
Anisfeld, AM ;
Kast-Woelbern, HR ;
Meyer, ME ;
Jones, SA ;
Zhang, YQ ;
Williams, KJ ;
Willson, T ;
Edwards, PA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (22) :20420-20428
[6]   Bile acid synthesis in cultured human hepatocytes:: Support for an alternative biosynthetic pathway to cholic acid [J].
Axelson, M ;
Ellis, E ;
Mörk, B ;
Garmark, K ;
Abrahamsson, A ;
Björkhem, I ;
Ericzon, BG ;
Einarsson, C .
HEPATOLOGY, 2000, 31 (06) :1305-1312
[7]   Clinical application of transcriptional activators of bile salt transporters [J].
Baghdasaryan, Anna ;
Chiba, Peter ;
Trauner, Michael .
MOLECULAR ASPECTS OF MEDICINE, 2014, 37 :57-76
[8]   Dual Farnesoid X Receptor/TGR5 Agonist INT-767 Reduces Liver Injury in the Mdr2-/- (Abcb4-/-) Mouse Cholangiopathy Model by Promoting Biliary HCO3- Output [J].
Baghdasaryan, Anna ;
Claudel, Thierry ;
Gumhold, Judith ;
Silbert, Dagmar ;
Adorini, Luciano ;
Roda, Aldo ;
Vecchiotti, Stefania ;
Gonzalez, Frank J. ;
Schoonjans, Kristina ;
Strazzabosco, Mario ;
Fickert, Peter ;
Trauner, Michael .
HEPATOLOGY, 2011, 54 (04) :1303-1312
[9]   Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis [J].
Bhatnagar, Sushant ;
Damron, Holly A. ;
Hillgartner, F. Bradley .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (15) :10023-10033
[10]  
Biagioli M, 2019, HANDB EXP PHARMACOL, V256, P95, DOI 10.1007/164_2019_225